Alphatec Holdings, Inc.
ATEC Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
What Alphatec Holdings, Inc. does
No business description yet.
- Legal name
- Alphatec Holdings, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 24, 2026
- Accession Β· CIK
- 0001193125-26-067393
0001350653
Revenue and margins
Alphatec Holdings, Inc. had $764M of revenue in fiscal 2025, up 25.0% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $2.8M in fiscal 2025, 0.4% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Alphatec Holdings, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 5.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Alphatec Holdings, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $187M | $84.7M | $221M | $139M | $161M |
| Debt incl. finance leases | $327M | $379M | $515M | $578M | $630M |
| Debt / equity | 4.1x | β | 6.6x | β | 50.7x |
| Interest coverage | β18.0x | β26.7x | β10.4x | β5.5x | β1.8x |
| Current ratio | 3.3x | 1.8x | 2.9x | 2.7x | 2.1x |
| Quick ratio | 2.4x | 1.1x | 2.0x | 1.6x | 1.3x |
| Total assets | $572M | $521M | $805M | $776M | $791M |
| Total liabilities | $491M | $556M | $727M | $790M | $779M |
| Shareholders' equity | $80.7M | β$34.7M | $78.1M | β$14.2M | $12.4M |
| Net debt (β = net cash) | $140M | $295M | $294M | $439M | $470M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 9 | 4 / 9 | 3 / 9 | 5 / 9 | 3 / 9 | 3 / 9 | 4 / 9 | 4 / 9 | 5 / 9 |
| Accruals ratio | β21.2% | 7.2% | β3.1% | β16.0% | β15.1% | β16.7% | β13.9% | β16.3% | β14.9% | β24.1% |
| Altman Z'' | β14.96 | β15.81 | β11.36 | β9.45 | β5.28 | β3.14 | β6.33 | β3.47 | β4.35 | β4.63 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $120M | $102M | $91.7M | $113M | $145M | $243M | $351M | $482M | $612M | $764M |
| Gross profit | $76.1M | $68.2M | $63.2M | $77.6M | $103M | $158M | $233M | $310M | $424M | $532M |
| Research and development | $9.2M | $4.9M | $9.9M | $13.8M | $18.7M | $32.0M | $44.0M | $70.1M | $80.7M | $76.3M |
| Operating income | β$15.4M | β$9.0M | β$22.4M | β$47.3M | β$58.9M | β$128M | β$147M | β$173M | β$136M | β$82.1M |
| Interest expense | $5.4M | β | β | $9.9M | $12.4M | $7.1M | $5.5M | $16.6M | $24.9M | $45.9M |
| Pretax income | β$30.9M | β$4.6M | β$30.2M | β$57.1M | β$78.8M | β$144M | β$152M | β$187M | β$162M | β$143M |
| Income tax | β$4.6M | β$0.0M | β$1.4M | β$0.2M | $0.1M | β$1.1M | β$0.7M | β$0.3M | $0.1M | β$0.0M |
| Net income | β$29.9M | β$2.3M | β$29.0M | β$57.0M | β$79.0M | β$143M | β$151M | β$187M | β$162M | β$143M |
| Net income to common | β | β$2.3M | β$42.5M | β$57.0M | β$79.0M | β$143M | β$151M | β$187M | β$162M | β$143M |
| Diluted EPS | β$3.49 | β$1.08 | β$1.20 | β$1.09 | β$1.18 | β$1.49 | β$1.46 | β$1.54 | β$1.13 | β$0.96 |
| Diluted shares | 0.01B | 0.01B | 0.04B | 0.05B | 0.07B | 0.10B | 0.10B | 0.12B | 0.14B | 0.15B |
| Cash flow | ||||||||||
| Cash from operations | β$10.0M | β$8.7M | β$25.6M | β$33.1M | β$46.4M | β$73.3M | β$75.1M | β$78.5M | β$44.7M | $45.2M |
| Capital expenditure | $8.9M | $7.6M | $6.5M | $13.0M | $23.1M | $68.5M | $49.5M | $80.5M | $83.2M | $42.5M |
| Free cash flow | β$18.9M | β$16.3M | β$32.1M | β$46.2M | β$69.5M | β$142M | β$125M | β$159M | β$128M | $2.8M |
| Depreciation and amortization | $12.4M | $7.5M | $6.8M | $7.6M | $10.9M | $26.8M | $41.2M | $56.1M | $78.4M | $77.5M |
| Stock-based compensation | $1.6M | $4.0M | $5.3M | $11.0M | $17.7M | $36.5M | $40.6M | $81.2M | $73.3M | $73.7M |
| Acquisitions | β | β | $15.1M | β | β | $62.1M | β | $55.0M | $0.0M | $0.0M |
| Share buybacks | β | β | β | β | β | $25.0M | β | β | β | β |
| Dividends and buybacks | β | β | β | β | β | $25.0M | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $19.6M | $22.5M | $29.1M | $47.1M | $108M | $187M | $84.7M | $221M | $139M | $161M |
| Total debt | $49.3M | $42.9M | $49.3M | $61.2M | $46.3M | $327M | $379M | $515M | $578M | $630M |
| Current assets | $72.8M | $66.5M | $75.5M | $108M | $184M | $331M | $256M | $451M | $417M | $451M |
| Current liabilities | $40.1M | $29.7M | $30.6M | $36.4M | $58.3M | $101M | $139M | $158M | $153M | $219M |
| Inventory | $30.1M | $27.3M | $28.8M | $34.9M | $46.0M | $91.7M | $102M | $137M | $175M | $169M |
| Property and equipment, net | $15.1M | $12.7M | $13.2M | $19.7M | $36.7M | $87.4M | $102M | $150M | $156M | $135M |
| Goodwill | $0.0M | β | $13.9M | $13.9M | $13.9M | $39.7M | $47.4M | $73.0M | $71.0M | $75.2M |
| Intangible assets | $5.7M | $5.2M | $26.4M | $25.6M | $24.7M | $85.3M | $82.8M | $102M | $93.5M | $93.5M |
| Total assets | $94.2M | $84.7M | $129M | $170M | $261M | $572M | $521M | $805M | $776M | $791M |
| Total liabilities | $136M | $111M | $112M | $126M | $131M | $491M | $556M | $727M | $790M | $779M |
| Shareholders' equity | β$41.5M | β$26.7M | $17.6M | $43.6M | $130M | $80.7M | β$34.7M | $78.1M | β$14.2M | $12.4M |
| Margins | ||||||||||
| Gross margin | 63.3% | 67.1% | 69.0% | 68.4% | 70.8% | 64.9% | 66.4% | 64.3% | 69.4% | 69.6% |
| Operating margin | β12.8% | β8.8% | β24.5% | β41.7% | β40.6% | β52.7% | β41.9% | β36.0% | β22.3% | β10.7% |
| EBITDA margin | β2.5% | β1.5% | β17.1% | β35.0% | β33.1% | β41.7% | β30.2% | β24.3% | β9.4% | β0.6% |
| Net margin | β24.9% | β2.3% | β31.6% | β50.3% | β54.5% | β58.8% | β43.1% | β38.7% | β26.5% | β18.8% |
| FCF margin | β15.7% | β16.0% | β35.0% | β40.7% | β48.0% | β58.3% | β35.5% | β33.0% | β20.9% | 0.4% |
| Returns | ||||||||||
| Return on capital | β | β | β46.9% | β64.7% | β67.9% | β45.9% | β44.7% | β36.8% | β25.3% | β13.5% |
| Return on capital employed | β28.4% | β16.4% | β22.7% | β35.4% | β29.0% | β27.2% | β38.5% | β26.8% | β21.9% | β14.4% |
| Return on equity | β | β | β | β186.3% | β91.1% | β135.9% | β657.7% | β859.1% | β507.1% | β |
| Return on assets | β31.8% | β2.6% | β27.1% | β38.1% | β36.6% | β34.3% | β27.7% | β28.1% | β20.5% | β18.3% |
| Return on tangible equity | β | β | β | β1,380.5% | β86.6% | β | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | β15.4% | β9.9% | 23.7% | 27.7% | 67.9% | 44.3% | 37.4% | 26.8% | 25.0% |
| Share count change | β | 54.8% | 165.9% | 47.9% | 28.3% | 43.5% | 7.5% | 17.3% | 17.9% | 5.0% |
| Financial health | ||||||||||
| Debt / equity | β | β | 2.8x | 1.4x | 0.4x | 4.1x | β | 6.6x | β | 50.7x |
| Interest coverage | β2.9x | β | β | β4.8x | β4.8x | β18.0x | β26.7x | β10.4x | β5.5x | β1.8x |
| Current ratio | 1.8x | 2.2x | 2.5x | 3.0x | 3.2x | 3.3x | 1.8x | 2.9x | 2.7x | 2.1x |
| Quick ratio | 1.1x | 1.3x | 1.5x | 2.0x | 2.4x | 2.4x | 1.1x | 2.0x | 1.6x | 1.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 7.4% | 7.5% | 7.1% | 11.5% | 16.0% | 28.2% | 14.1% | 16.7% | 13.6% | 5.6% |
| Stock comp / revenue | 1.4% | 3.9% | 5.8% | 9.7% | 12.2% | 15.0% | 11.6% | 16.8% | 12.0% | 9.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 4.0 | 3.0 | 5.0 | 3.0 | 3.0 | 4.0 | 4.0 | 5.0 |
| Altman Z'' | β15.0 | β15.8 | β11.4 | β9.5 | β5.3 | β3.1 | β6.3 | β3.5 | β4.3 | β4.6 |
| Accruals ratio | β21.2% | 7.2% | β3.1% | β16.0% | β15.1% | β16.7% | β13.9% | β16.3% | β14.9% | β24.1% |
Source: SEC EDGAR XBRL filings (CIK 0001350653). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.